



COPY OF PAPERS
ORIGINALLY FILED

Receipt
#3

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE
(Attorney Docket No. 107823.127US7)

Application of: Madiyalakan) Examiner: Not Yet Assigned
Serial No: 09/994,466)
Filed: November 26, 2001) Art Unit: 1614

For: THERAPEUTIC BINDING AGENTS AGAINST MUC-1 ANTIGEN AND METHODS FOR THEIR USE

CERTIFICATE OF FIRST CLASS MAILING UNDER 37 CFR 1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to: Commissioner for Patents, Washington, DC 20231, Attention: OIPE Customer Service Center, on the date indicated below.

Date: 12/08/01

Heather K. May
Heather May

Commissioner for Patents
Washington, D.C. 20231
Attention: OIPE Customer Service Center

REQUEST FOR CORRECTED FILING RECEIPT


Sir:

Attached is a copy of the formal filing receipt for the above-referenced application. Please correct the "Domestic Priority as Claimed by Applicant" section to read as follows:

THIS APPLN IS A CIP OF 09/724,094 11/28/2000
WHICH IS A CIP OF 09/641,833 08/18/2000
AND CLAIMS BENEFIT OF 60/270,471 02/21/2001
AND CLAIMS BENEFIT OF 60/270,456 02/21/2001
AND CLAIMS BENEFIT OF 60/164,714 11/11/1999
AND CLAIMS BENEFIT OF 60/149,492 08/18/1999

Please charge any fees which may be due in connection with this matter to deposit account 08-0219. If there are any questions, please call the undersigned at the telephone number indicated below.

Respectfully submitted,



Nancy Chiu, Ph.D., Reg. No. 43,545
Agent for Applicant

Date: December 28, 2001

HALE AND DORR LLP
60 State Street
Boston, MA 02109
(617) 526-6000
(617) 526-5000 (Facsimile)



UNITED STATES PATENT AND TRADEMARK OFFICE

COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 20231
www.uspto.gov

APPLICATION NUMBER	FILING DATE	GRP ART UNIT	FIL FEE REC'D	ATTY.DOCKET.NO	DRAWINGS	TOT CLAIMS	IND CLAIMS
09/994,466	11/26/2001	1614	0.00	107823.127	12	41	9

CONFIRMATION NO. 7223

23483
HALE AND DORR, LLP
60 STATE STREET
BOSTON, MA 02109

FILING RECEIPT



OC000000007163393

Date Mailed: 12/06/2001

Receipt is acknowledged of this nonprovisional Patent Application. It will be considered in its order and you will be notified as to the results of the examination. Be sure to provide the U.S. APPLICATION NUMBER, FILING DATE, NAME OF APPLICANT, and TITLE OF INVENTION when inquiring about this application. Fees transmitted by check or draft are subject to collection. Please verify the accuracy of the data presented on this receipt. If an error is noted on this Filing Receipt, please write to the Office of Initial Patent Examination's Customer Service Center. Please provide a copy of this Filing Receipt with the changes noted thereon. If you received a "Notice to File Missing Parts" for this application, please submit any corrections to this Filing Receipt with your reply to the Notice. When the USPTO processes the reply to the Notice, the USPTO will generate another Filing Receipt incorporating the requested corrections (if appropriate).

Applicant(s)

Ragupathy Madiyalakan, Residence Not Provided;

Domestic Priority data as claimed by applicant

THIS APPLN CLAIMS BENEFIT OF 60/270,471 02/21/2001
AND CLAIMS BENEFIT OF 60/270,456 02/21/2001
AND CLAIMS BENEFIT OF 60/164,714 11/11/1999
AND CLAIMS BENEFIT OF 60/149,492 08/18/1999

Foreign Applications

If Required, Foreign Filing License Granted 12/06/2001

Projected Publication Date: To Be Determined - pending completion of Missing Parts

Non-Publication Request: No

Early Publication Request: No


** SMALL ENTITY **

Title

Therapeutic binding agents against MUC-1 antigen and methods for their use

Preliminary Class

HALE & DORR DOCKETING
107823.127
Action Date _____
Priority to be Taken _____
Docketed by AA, 12/11/01



**LICENSE FOR FOREIGN FILING UNDER
Title 35, United States Code, Section 184
Title 37, Code of Federal Regulations, 5.11 & 5.15**

GRANTED

The applicant has been granted a license under 35 U.S.C. 184, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" followed by a date appears on this form. Such licenses are issued in all applications where the conditions for issuance of a license have been met, regardless of whether or not a license may be required as set forth in 37 CFR 5.15. The scope and limitations of this license are set forth in 37 CFR 5.15(a) unless an earlier date indicated is the effective date of the license, unless an earlier license of similar scope has been granted under 37 CFR 5.13 or 5.14.

This license is to be retained by the licensee and may be used at any time on or after the effective date thereof unless it is revoked. This license is automatically transferred to any related applications(s) filed under 37 CFR 1.53(d). This license is not retroactive.

The grant of a license does not in any way lessen the responsibility of a licensee for the security of the subject matter as imposed by any Government contract or the provisions of existing laws relating to espionage and the national security or the export of technical data. Licensees should apprise themselves of current regulations, especially with respect to certain countries, of other agencies, particularly the Office of Defense Trade Controls, Department of State (with respect to Arms, Munitions and Implements of War (22 CFR 121-128)); the Office of Export Administration, Department of Commerce (15 CFR 370.10 (j)); the Office of Foreign Assets Control, Department of Treasury (31 CFR Parts 500+) and the Department of Energy.

NOT GRANTED

No license under 35 U.S.C. 184 has been granted at this time, if the phrase "IF REQUIRED, FOREIGN FILING LICENSE GRANTED" DOES NOT appear on this form. Applicant may still petition for a license under 37 CFR 5.12, if a license is desired before the expiration of 6 months from the filing date of the application. If 6 months has lapsed from the filing date of this application and the licensee has not received any indication of a secrecy order under 35 U.S.C. 181, the licensee may foreign file the application pursuant to 37 CFR 5.15(b).